Basit öğe kaydını göster

Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

dc.contributor.authorKAYNAR, LEYLAGÜL
dc.contributor.authorBOLAMAN, ALİ ZAHİT
dc.contributor.authorTeke, Havva Uskudar
dc.contributor.authorAtalay, Figen
dc.contributor.authorALTUNTAŞ, FEVZİ
dc.contributor.authorSalihoglu, Ayse
dc.contributor.authorBEKSAÇ, MERAL
dc.contributor.authorSeval, Guldane Cengiz
dc.contributor.authorPAYDAŞ, SEMRA
dc.contributor.authorTuglular, Tulin Firatli
dc.contributor.authorARSLAN, ÖNDER
dc.contributor.authorGÖKER, HAKAN
dc.contributor.authorYurttas, Nurgul Ozgur
dc.contributor.authorGÜRMAN, GÜNHAN
dc.contributor.authorCakar, Merih Kizil
dc.contributor.authorAlbayrak, Murat
dc.contributor.authorKabukcu, Sibel Hacioglu
dc.contributor.authorYILMAZ, MEHMET
dc.contributor.authorTOPÇUOĞLU, PERVİN
dc.contributor.authorDEMİR, AHMET MUZAFFER
dc.contributor.authorSÖNMEZ, MEHMET
dc.contributor.authorPEHLİVAN, MUSTAFA
dc.date.accessioned2021-03-03T09:25:08Z
dc.date.available2021-03-03T09:25:08Z
dc.date.issued2019
dc.identifier.citationBEKSAÇ M., Seval G. C. , PAYDAŞ S., Tuglular T. F. , ARSLAN Ö., GÖKER H., KAYNAR L., ALTUNTAŞ F., Atalay F., Teke H. U. , et al., "Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey", CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.19, sa.10, 2019
dc.identifier.issn2152-2650
dc.identifier.othervv_1032021
dc.identifier.otherav_1ce825ee-bc1e-4ef7-9f4b-894f8fed5950
dc.identifier.urihttp://hdl.handle.net/20.500.12627/24656
dc.identifier.urihttps://doi.org/10.1016/j.clml.2019.09.402
dc.language.isoeng
dc.subjectONKOLOJİ
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectHEMATOLOJİ
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectOnkoloji
dc.subjectHematoloji
dc.titleElotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey
dc.typeMakale
dc.relation.journalCLINICAL LYMPHOMA MYELOMA & LEUKEMIA
dc.contributor.departmentAnkara Üniversitesi , ,
dc.identifier.volume19
dc.identifier.issue10
dc.contributor.firstauthorID269451


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster